MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,871K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Loss on issuance of warrants
Proceeds from equity line of cre...
Others
Negative Cash Flow Breakdown
Net loss
Non-cash gain on settlement of l...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Loss (gain) on sale of marketable investments
-
18
Net loss
-3,284
-6,499
Depreciation of property and equipment
9
19
Abandonment and expiration of patents and trademark rights
82
615
Amortization of patent, trademark rights
45
94
Non-cash lease expense
-59
-81
Equity-based compensation
0
60
Gain on sale of marketable securities
17
-
Amortization of financial obligation
69
183
Change in fair value of warrants
-670
-
Loss on issuance of warrants
-3,977
0
Non-cash gain on settlement of liability
-3,041
-
Prepaid expenses and other current assets
-24
-9
Lease liability
-56
-78
Funds receivable from new jersey net operating loss
-
0
Other assets
11
-761
Accounts payable
-2,570
914
Accrued expenses
287
-33
Net cash used in operating activities
-5,079
-3,892
Proceeds from sale of marketable securities
296
2,026
Purchase of marketable securities
0
91
(purchase) abandonment of patent and trademark rights
0
283
Net cash provided by investing activities
296
1,652
Proceeds from issuance of common stock and warrants
7,314
-
Proceeds from sale of stock, net of issuance costs
-398
765
Proceeds from note payable, net of issuance costs
0
250
Repayment of debt with cash
660
-
Proceeds from issuance of equity warrants
-
0
Proceeds from equity line of credit
398
-
Net cash provided by financing activities
6,654
1,015
Net increase (decrease) in cash and cash equivalents
1,871
-1,225
Cash and cash equivalents at beginning of period
1,701
-
Cash and cash equivalents at end of period
2,347
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$7,314K
Proceeds from sale of
marketable securities
$296K
Proceeds from equity line
of credit
$398K
Net cash provided by
financing activities
$6,654K
Net cash provided by
investing activities
$296K
Canceled cashflow
$1,058K
Net increase
(decrease) in cash and cash...
$1,871K
Canceled cashflow
$5,079K
Repayment of debt with cash
$660K
Proceeds from sale of
stock, net of issuance...
-$398K
Loss on issuance of
warrants
-$3,977K
Accrued expenses
$287K
Abandonment and expiration
of patents and...
$82K
Amortization of financial
obligation
$69K
Non-cash lease expense
-$59K
Amortization of patent,
trademark rights
$45K
Prepaid expenses and
other current assets
-$24K
Depreciation of property and
equipment
$9K
Net cash used in
operating activities
-$5,079K
Canceled cashflow
$4,552K
Net loss
-$3,284K
Non-cash gain on
settlement of liability
-$3,041K
Accounts payable
-$2,570K
Change in fair value of
warrants
-$670K
Lease liability
-$56K
Gain on sale of
marketable securities
$17K
Buy us a coffee
AIM ImmunoTech Inc. (AIMI)
AIM ImmunoTech Inc. (AIMI)